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Lentiviral vectors (LV) transduce quiescent cells, and provide stable integration to  
maintain transgene expression. Several approaches have been adopted to optimize LV safety  
profiles. Similarly, LV targeting has been tailored through strategies including the modification of  
envelope components, the use of specific regulatory elements, and the selection of appropriate  
administration routes. Models of aortic disease based on a single injection of pleiotropic LVs have  
been developed which efficiently transduce the three aorta layers in wild type mice. This  
approach allows the dissection of pathways involved in aortic aneurysm formation and the  
identification of targets for gene therapy in aortic diseases. LVs provide a fast, efficient, and  
affordable alternative to genetically modified mice to study disease mechanisms and develop  
therapeutic tools.   
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Novel Applications of Lentiviral Vectors  
Lentiviruses (LV) are a type of retrovirus able to transduce quiescent cells, although this  
process is less efficient than transduction of stimulated or low proliferative cells such as  
hematopietic stem cells (HSCs). These viruses express reverse transcriptase, which transforms  
viral RNA into DNA. Viral DNA stably inserts into the host genome through the action of viral  
integrase. Engineered LVs optimized to fulfill biosafety requirements, with improved target  
specificity and more efficient transduction (see Glossary), constitute effective tools for long- 
term gene modification in vivo. LVs avoid several major drawbacks associated with gene  
delivery through adenovirus (AdV) or adeno-associated virus (AAV) systems, such as the  
induction of an intense inflammatory response and transient transgene expression in the case  
of AdVs and the complex production protocols and low cargo capacity of AAVs (e.g., while LV  
packaging capacity is up to 8Kb, AAV cargoes cannot exceed 4.5Kb). LVs efficiently transduce  
nondividing differentiated cells and stably integrate into the host-cell genome while generating  
only a moderate immune response (Table 1)[1,2,3]. These features make LVs optimal tools for  
a number of purposes, including gene therapy and in vivo dissection of molecular pathways  
involved in pathophysiological processes. In this opinion article, we examine general topics  
related to the in vivo applications of LVs, with particular emphasis on safety concerns and  
methods to improve target selectivity. We propose applications of LVs in the identification of  
therapeutic targets and the evaluation of candidate treatments, as well as the potential use of  
LV transduction for gene therapy in aortic diseases. Finally, we discuss our view that these  
unique LV properties make these vectors an optimal system for disease model development.  
  
Biosafety Issues   
The occurrence of leukemogenesis due to insertional mutagenesis in either X-linked  
SCID or Wiskott-Aldrich syndrome patients treated with gammaretroviral vectors [4,5]  
reinforced the importance of biosafety as a central concern in gene therapy. Strategies aimed  
at achieving satisfactory biosafety levels in LV applications in vivo have been progressively  
adopted, leading to successful administration of LV for gene therapy of diseases as  Wiskott- 
Aldrich syndrome, X-adrenoleukodystrophy, metachromatic leukodystrophy, and others  
[5,6,7]. This approach has given rise to successive generations of LVs with increasingly  
sophisticated biosafety characteristics. For example, modification of LV elements has helped to  
reduce critical risks, such as LV replication in vivo leading to undesired transduction events, and  
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insertional mutagenesis that could lead to cancer. Intercellular transmission of vector  
components beyond first-line transduction needs to be prevented in order to avoid the spread  
of potentially deleterious sequences. Approaches used to achieve this include the generation  
of a split viral genome, together with the deletion of accessory genes, aimed at reducing the  
production of replication-competent viral particles in packaging cells. Thus, LV genome is  
usually distributed into several plasmids, which comprise a transfer plasmid (encoding the  
transgene of interest), one or two packaging plasmids, and an envelope plasmid. In 3rd  
generation LV, most original viral packaging components are removed, and the remaining are  
distributed in two plasmids; besides, to overcome the elimination of Tat protein, a Tat- 
independent 5' LTR is included in the transfer plasmid. Additionally, strategies leading to ad hoc  
modification of LV tropism restrict transduction to specific cell types (see below), and  
contribute to limit off-target effects [8]. LVs usually integrate into transcriptionally active  
genomic areas, but unlike gammaretroviruses they show no preference for promoter regions.  
This integration pattern is associated with the activity of LEDGF/p75, which links host DNA to  
LV integrase [9,10]. However, insertional mutagenesis upon LV integration remains a critical  
safety concern, and different strategies have been adopted to reduce this potential risk, such  
as the elimination of enhancer/promoter sequences from the LTRs to produce self-inactivating  
(SIN) LVs. Similarly, integration-deficient LVs (IDLV) with class I integrase mutations and a low  
integration rate are being developed. IDLV remain as episomes in the host cell, and are thus  
suitable for sustained gene expression in quiescent cells or transient modification of  
proliferative cells [11]. Despite the safer profile of IDLV, several concerns have arisen related to  
their in vivo efficacy. Hence, transduction with IDLV yields lower transgene expression as  
compared to LV; also, long-term follow up studies have reported a substantial decrease in  
transgene expression in mice after 1 year in organs as liver and cerebellum, whereas in retina  
sustained GFP expression has been reported for at least 9 months [11,12,13]. Combinations of  
IDLVs encoding Zn finger nucleases and a DNA template of interest have been used successfully  
for safe site-directed integration of exogenous DNA sequences into the host genome [14].  
Further approaches to circumvent insertional mutagenesis include the generation of self- 
deleting LVs and transposon hybrids [15] (Box 1).  
A major restraint for systemic LV administration in vivo is the activation of host innate and  
adaptive immune responses to LV components or the transgene product, which can lead to the  
clearance of LVs or LV-transduced cells, as shown in baboons subjected to myeloablative  
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conditioning [16]. Systemic inoculation with LVs triggers a transient type I IFN increase in  
mouse liver, mainly mediated by the recognition of viral ssRNA by TLRs, especially TLR3 and  
TLR7. This response, probably initiated by plasmacytoid dendritic cells, limits transduction of  
and transgene expression in hepatocytes in vivo [17,18]. Additionally, the induction by IFN of  
some restriction factors, like tetherin, effectively prevents virus replication in host cells, as  
demonstrated in HeLa cell line [19]. Specific immune responses against exogenous transgene- 
encoded proteins also interfere with in vivo LV efficiency; however, this issue can be avoided  
by introducing target sequences for dendritic cell-specific miRNAs into the 3’ UTR of the  
transgene of interest. The suppression of transgene expression through this approach largely  
depends on a threshold amount of endogenous miRNA, which can be exploited to selectively  
target cells in a particular functional state [20]. Additionally, specific targeting of LVs to  
hepatocytes may circumvent the host immune response. This strategy has been successfully  
used to achieve sustained production of human factor IX in a murine model [21]. Interestingly,  
mass spectometry analysis of MHC-I in human HEK 293T, D407, and HER 911 cell lines  
transduced with LVs in vitro reveals a lack of MHC-I-presented transgene-derived peptides,  
together with changes in the repertoire of MHC-I-presented self-peptides. This response could  
promote an autoimmune condition in susceptible individuals [22].   
In summary, although engineering of viral components reduces biosafety risks and the  
triggering of host immune responses, the development of potential LV-related side effects is  
an eventuality that must be taken into consideration. Long-term monitoring of patients  
undergoing LV-based gene therapy will be critical to assess the actual incidence and nature of  
these events, and to advance new strategies to optimize LV characteristics.   
  
Targeting strategies  
A priority in disease modeling with LVs is to develop strategies to ensure spatial or temporal  
restriction of vector delivery and transgene expression, thus avoiding transfer of genetic  
material to off-target or potentially dangerous cells. Below, we discuss major targeting  
strategies focused either on engineering LV components to efficiently re-direct LV particles  
toward the desired cell type or on the selection of specific LV administration routes.  
  
Main targeting strategies  
LV particles can be selectively targeted either by modifying vector surface characteristics to  
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optimize LV binding to the target cell or by including regulatory sequences in the cargo whose  
expression is restricted to the selected target cell type. Viral tropism is primarily dependent on  
glycoproteins present in the LV envelope, since these are recognized by membrane receptors  
not expressed on all cells. For instance, the VSV-G envelope binds to the LDL receptor; since  
this receptor is absent from the surface of resting T lymphocytes, these cells are resistant to  
VSV-G transduction [23]. LVs can thus be engineered to express particular envelope  
glycoproteins (pseudotyped) to either induce or avoid preferential binding to selected cell  
types. VSV-G is the most frequently used virus for pseudotyping, although other viral envelopes  
are also used, such as rabies, measles virus, Ebola, and Sindbis virus [24]. However, precise LV  
targeting usually involves the generation of chimeric glycoproteins fused to ligands, IgG, or  
single-chain variable fragments (scFvs), which recognize specific cell surface receptors.  
Envelope glycoproteins with separate membrane fusion and receptor binding functions are  
preferentially used for this approach, as in the case of Sindbis and measles virus [25,26].  
  
Targeting of vascular cells  
Vascular disease can affect different vascular beds throughout the body and includes a  
variety of entities, including atherosclerotic peripheral and carotid arterial diseases, aortic  
aneurysm, Raynaud’s phenomenon, and Buerger disease. LV transduction of vascular cells in  
vivo allows the investigation and manipulation of specific molecular mechanisms involved in  
vascular disease progression and the identification of potential therapeutic targets. LV-based  
approaches have been used either to prevent disease or to develop preclinical models of  
diseases that occur with pathological vascular wall remodeling, such as atherosclerosis,  
restenosis, and aortic aneurysm. These approaches have led to the identification of disease- 
mediating pathways, particularly for aortic aneurysm [27,28,29].  
Most blood vessels are composed of three layers: the tunica intima (inner layer) consists of  
a single layer of ECs supported by a subendothelial connective tissue layer; the tunica media  
(middle layer) contains circular elastic fibers, connective tissue, and VSMCs; the tunica  
adventitia, the outermost layer, is formed of connective tissue. Capillaries lack the media and  
adventitia, having only a single layer of ECs and connective tissue.  
Within blood vessels, ECs cover the entire luminal vessel surface, and are therefore  
potentially more accessible to transduction by parenteral LV administration without specific  
targeting. Accordingly, functional data demonstrate efficient transduction and gene  
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modification of mouse aorta ECs upon systemic injection of pleiotropic LVs through the jugular  
vein. LVs transduce all three aortic layers efficiently, and histology at very early post- 
inoculation stages -1 day after transduction- reveals transduction of ECs, VSMCs, and cells of  
the adventitia (Fig. 1, 2). In our opinion, these results indicate that transduction does not  
spread gradually from the intima to the adventitia, but rather that LVs can transduce cells of  
the outer layers of the vascular wall through additional routes that do not necessarily involve  
intima transduction, such as potential LV access to adventitia through vasa vasorum [27,28,30].  
In addition, ECs from different vascular beds display heterogeneous functional characteristics  
in vivo [31], which can be exploited to selectively target a specific blood vessel type for analysis.  
For example, LVs engineered to express an scFv specific for the EC marker endoglin (CD105)  
show high selectivity for liver sinusoidal ECs after intravenous (i.v.) tail-vein inoculation in mice  
[32]. The incorporation of EC-specific regulatory elements into the LV-encoded cargo sequence  
has also achieved efficient specific EC targeting in vivo. Several EC-specific promoters were  
tested, including those from the Tie1, Tie2, Flk-1, VE-Cadherin, and ICAM-2 genes; of these, the  
Tie2 promoter/enhancer -also active in HSCs and monocytes- was the most EC-selective,  
driving preferential transgene expression in ECs in vitro and in the small tumor vasculature  
after systemic tail-vein LV injection in mice [33]. Similarly, specific modification of TLR4  
expression in lung ECs has been achieved with the VE-cadherin promoter [34]. Interestingly,  
combination of several targeting strategies significantly enhances specificity. Thus, dual- 
targeted LVs carrying a surface anti-CD146 antibody and simultaneously encoding the Tie2  
promoter/enhancer showed higher specificity than single-modified LV versions in primary  
human ECs in vitro [35].  
VSMCs have been successfully targeted using LVs pseudotyped with the Hantavirus  
envelope in a rabbit model of carotid injury [36] and through the cloning of the SMC-specific  
promoter SM22, which specifically drives expression of miRNA-145 in aortic VSMCs after tail- 
vein LV injection in Apoe-/- mice [37]. In addition, intratracheally instilled LVs bearing a miRNA  
targeting the SM22 gene—a cytoskeleton protein involved in vascular remodeling and  
hypoxic pulmonary hypertension—specifically modulate gene expression in pulmonary arterial  
SMCs. In this case, LV specificity resides in selective expression of SM22 in this cell type [38].  
Many authors suggest that in vivo VSMC transduction largely depends on the loss of EC layer  
integrity, for example by mechanical disruption with a balloon catheter introduced into the  
carotid artery and inflated in situ to produce EC injury [36]. Indeed, ECs are considered a barrier  
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to LVs that is only overcome by EC injury or in specialized areas such as capillary beds, liver  
sinusoids, or kidney glomeruli. LV entry is impeded by adherens junction formation in epithelial  
cells, and this effect is blocked by E-cadherin knockdown. VE-cadherin has been proposed to  
play a similar role in virus traffic through the EC layer [39,40]. Interestingly, intrajugular  
inoculation of VSV-G-pseudotyped LVs in several mouse models (wild type, Apoe -/-, and MT4- 
MMP deficient mice) has yielded functional VSMC transgene expression of GFP-fused  
calcineurin-blocking LxVP peptide, Adamts-1 shRNA, and MT4-MMP. This LV-based approach  
has allowed to dissect the role of VSMCs in aortic disease development (Fig.1, 2) [27,28,29].  
VSMC transduction in vivo has also been reported upon tail-vein injection of LV encoding  
Smad7 shRNA or miR-29b pre-miR constructs [41,42]. The access route to VSMC has not been  
delineated, but several mechanisms could account for the efficient targeting of these cells. For  
example, in experiments conducted in Apoe -/- or Smad3+/- mice, EC dysfunction may have  
altered barrier function to facilitate LV transduction of the medial layer (Fig. 2) [27,41,42].  
Furthermore, VSMCs have been successfully transduced by intrajugular LV inoculation in MT4- 
MMP-deficient neonatal mice, which may allow easier LV access through the EC barrier (Fig.2)  
[29]. However, a similar degree of VSMC transduction can be observed in wild type adult  
C57BL/6 mice when knocking down Adamts1 to address the role of this metalloproteinase in  
aortic aneurysm and medial degeneration (Fig.1, 2). Thus, VSMC transduction has been  
achieved empirically by intrajugular injection of pleiotropic LVs. In our opinion these data  
refute the hypothesis that viral vectors can transduce VSMC only if endothelial permeability is  
altered, a hypothesis based on data obtained with AdV or LV in preclinical models of carotid  
injury, which show VSMC transduction only in areas of EC denudation [34,43]. We consider  
that the lack of VSMC transduction upon tail-vein injection reported by some groups could be  
due to differences in the administration route, viral vector type, and virus titer. For instance,  
viruses have been inoculated systemically through the tail vein [44,45,46] or locally into the  
target vessel [34,47,48], whereas in the models discussed above LVs are delivered by  
intrajugular injection [27,28,39], which could affect viral vector distribution. Many groups have  
used AdVs instead of LVs to modulate in vivo gene expression [43,45,47,48], and VSMC  
transduction efficiency may also be influenced by differences in viral vector tropism or  
biodistribution. Furthermore, inoculation of different amounts of viral particles could partially  
account for discrepancies in in vivo distribution. Studies analyzing the number of AdV particles  
required to efficiently transduce ECs in vivo have determined an optimal dose of 1010-1011  
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infective particles per animal to achieve a maximal transgene expression in target cells [47]. In  
contrast, the number of infective LV particles employed in most in vivo analyses is around 107  
per animal [37,44,49], although the relative transduction efficiency between AdVs and LVs has  
not been firmly established. In studies mentioned above, successful transduction of VSMCs has  
been achieved by inoculating 108 active LV particles per mouse, which could explain the  
efficient transduction of all aortic layers [27,28,29]. Additional processes may have allowed  
VSMC transduction in these assays. For example, VSV-G-pseudotyped particles can be retained  
in fibronectin-rich extracellular matrix and transmitted to secondary cellular targets [50].  
Moreover, viral particle transcytosis has been described for adenovirus (e.g. transferrin  
receptor-mediated transcytosis in Caco-2 cells), HIV, and HTLV1 in an in vitro model of  
epithelial tight barrier [51,52].  Hence, despite the actual mechanisms involved have not been  
determined yet, our view is that VSMCs are clearly susceptible of transduction by LV in the  
presence of a conserved endothelial layer; and that the study of the mechanisms responsible  
for this will provide invaluable information on LV behavior in vivo. Several LV targeting  
strategies have been used to transduce other cell types, including dendritic cells [53],  
lymphocytes [54], astrocytes [55], tumor cells [56], and hematopoietic progenitors [57].  
  
Relevance of the administration route  
LVs can be delivered either systemically—usually by intraperitoneal or intravenous  
injection—or locally to specific tissues or organs where the gene modification is desired. The  
choice of a particular administration route also contributes to the organ and tissue distribution  
of LV particles. As mentioned, systemic inoculation usually requires modification of viral  
tropism or the incorporation of specific regulatory sequences to ensure selective transduction  
of target cells. However, in some cases, systemic administration of LVs through a specific route  
is enough to favor tropism toward a defined cell type. For example, in a mouse model of  
inflammatory arthritis, intraperitoneal injection preferentially targets pleiotropic VSV- G- 
pseudotyped LVs to activated macrophages [58]. This might be due to the intrinsic tropism of  
LVs for myeloid-lineage cells [59], but could also reflect the activation state of macrophages in  
these experiments, which might make them more susceptible to LV transduction. Furthermore,  
local administration protocols have been developed to limit spatial LV distribution. Locally  
restrained LV delivery generally leads to transduction of several cell types, which may provide  
a route to study the coordinated contribution of these cells to a given process or the global  
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effect of a genetic modification on the selected organ or structure. Local administration can  
also be combined with LV engineering to analyze the role of a specific cell type in the selected  
location. Examples of local LV delivery include intramyocardial administration in adult rats [60],  
intrafemoral injection for in situ transduction of hematopioetic stem cells in mice [61],  
intrathymic inoculation to target T-cell precursors in ZAP-70–deficient mice [62], and  
stereotactic injection at specific brain areas in rodents [63].  
   
Lentiviral vectors in aortic disease modeling  
The in vivo applications of LVs depend on their capacity for stable delivery, whether the  
cargo is single genes under ubiquitous or lineage-restricted regulatory elements, complex  
genetic structures in polycistronic cassetes, or shRNAs for functional interrogation of genes of  
interest. These characteristics, combined with the easy modulation of their immunogenicity  
and biodistribution properties, make them an invaluable tool in basic and translational  
research. The wide-ranging applications of LVs include LV-mediated transgenesis, immune  
modulation and vaccine development, in vivo cell imaging and lineage tracking, and  
reprogramming of pluripotent cells (reviewed in 2). Furthermore, LVs are now emerging as a  
useful means for dissecting molecular pathways involved in pathophysiological conditions and  
the design of preclinical models of disease. Conventional validation of putative targets based  
on genetic ablation of endogenous genes has provided invaluable information on disease  
mechanisms; however, our notion is that this approach is expensive and has limited versatility,  
since it is hard to achieve accurate temporal regulation of gene depletion in one or more cell  
types located in a given tissue or organ. We thus believe that there is a clear need for affordable  
and versatile disease models that support precise, spatio-temporally regulated gene  
modification in vivo.   
  
LVs and preclinical models of aortic disease  
Mouse models of aortic aneurysm have advanced from giving a merely mechanistic  
perspective—for example, through chemically-induced abdominal aortic aneurysm with  
elastase or calcium chloride infusion [64,65]—to providing information on molecular pathways  
involved in aortic aneurysm progression in knockout mice. Mice deficient in Lox, MMP-3, TIMP- 
1, LDL receptor, or ApoE develop abdominal aortic aneurysm in basal conditions or upon Ang  
II treatment [66-69]. Similarly, mouse models of Marfan syndrome (MFS), which carry a knock- 
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in mutation in the Fbn1 locus, develop thoracic aortic aneurysm associated with altered  
TGFand AngII pathways [70]. However, these models do not allow gene ablation at a specific  
stage of aortic aneurysm progression, which could help to define the specific stages when  
mediators act. The generation of inducible, tissue-specific knockout mice is a tedious, time- 
consuming and often leaky approach. By silencing Adamts1 through LV-mediated shRNA  
delivery at a defined time point, characteristic changes in medial architecture may be induced  
together with strong dilation of the aortic ring, ascending aorta, and abdominal aorta in wild  
type mice, with progression to aneurysms in 13 of 16 animals and lethal dissections in 4 of 16  
mice upon Ang II treatment [28]. This LV-based strategy allowed to determine the pathogenic  
sequence of thoracic aortic aneurysm generation, with Adamts1 participating in blood pressure  
changes and matrix degradation at early stages followed by involvement of the TGF-β–Smad  
pathway. This fast and highly controlled approach also led to the identification of nitric oxide  
(NO) as an essential thoracic aortic aneurysm mediator [28]. Using a similar approach, MT4- 
MMP activity has been shown to regulate the VSMC contractile phenotype and to be essential  
for preventing thoracic aortic aneurysm development [29]. Moreover, systemic intrajugular  
inoculation of pleiotropic LVs allowed identifying the decisive role of VSMCs in thoracic aortic  
aneurysm, despite the putative barrier function of ECs. While this approach cannot achieve  
specific cell targeting, further LV modification could enable dissection of the contribution of  
specific cell types at selected stages. The adequate transgene expression window for the  
accurate modeling of aortic disease may be further determined with LV bearing drug-inducible  
promoters, as those regulated by doxycycline-dependent transactivators in Tet On/Tet off  
systems [71]. This method allows switching on and off transgene expression at desired times,  
and analyzing the pathogenic role of a given molecule at a specific point of disease  
development. Tet–based systems can be combined with tissue-specific promoters driving  
transactivator expression [72], which facilitate the analysis of temporal involvement of  
selected cell types in disease onset and evolution. With knockout technology, this would be  
barely achievable and would require the generation of mouse strains with multiple  
conditionally inducible floxed alleles, which is definitely a time-consuming, expensive and  
technically challenging approach.   
  
LVs as therapeutic tools for aortic disease  
In addition to disease modeling, we postulate that this strategy can be advantageously used  
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for therapy. LV integration leads to sustained transgene expression, and therefore a single 
inoculation of these vectors could achieve stable gene modification in chronic diseases. Indeed, 
transgene expression in the aortic wall has been detected for at least 49 days after intra jugular 
LV inoculation [28]. Although a longer and more sustained transgene expression can be 
anticipated, new cells might be recruited to inflamed or remodeling tissues at later stages, after 
LV administration. In this scenario, repeated LV doses may be needed to achieve a prolonged 
beneficial effect in vivo. On the other hand, the use of inducible LV systems (see above) may 
be very useful to establish the appropriate therapeutic window, and to provide a way to rapidly 
switch off the expression of the transgene in case a severe side effect is detected. 
Cardiovascular diseases are currently being targeted in several gene therapy clinical trials (e.g. 
NCT03039751, NCT02844283, NCT01002430, NCT00787059, NCT00620217, NCT00117650, 
and NCT00000431), but none of them addresses the treatment of aortic disease 
(www.clinicaltrials.gov). Data from genetically modified preclinical models suggest that specific 
gene targeting through viral vectors could be an effective therapeutic approach for aortic 
aneurysm [73]. Supporting this view, LV-mediated re-expression of MT4-MMP in VSMCs is 
enough to prevent aneurysm formation in MT4-MMP–deficient mice [29]. Likewise, an LV-
based approach has been used to express peptide sequences that specifically block abdominal 
aortic aneurysm development and inflammation [27,58,74]. We believe that this experimental 
evidence provides a valuable in vivo proof-of-concept that encourages the use of LVs for gene 
therapy in human aortic disease. For example, recent findings show that pharmacological NOS2 
inhibition results in LV-mediated regression of aortic dilation in MFS mice [28]. Given the 
preferential transduction of aorta by intrajugular-delivered LVs, NOS2 silencing may represent 
a gene therapy alternative that would circumvent potential side effects derived from systemic 
treatment with NOS2 inhibitors.  
LV-based gene therapy is an emerging field with promising results in the treatment of a 
number of human diseases. However, LV application in the therapy of aortopathies still needs 
to overcome some obstacles. Most of LV-based therapies are currently carried out through ex 
vivo transduction of target cells (e.g. HSCs, T lymphocytes), which are subsequently inoculated 
back in patients. This procedure leads to a lower risk of systemic secondary effects derived 
from off-target transduction events, and requires a reduced amount of LV particles. Although 
direct in vivo inoculation of LV is also being conducted to treat some conditions as retinopathy 
and Parkinson’s disease [75,76], therapy of those aortic diseases with VSMC involvement 
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probably requires large amounts of GMP-produced LV, and needs a careful LV design to limit  
the generation of side effects derived from systemic LV administration (see above). In addition,  
unlike monogenic diseases as -thalassemia or Wiskott Aldrich syndrome, a precise dissection  
of mediators involved in aortic disease and their functional networks is needed prior to the  
application of LV in gene therapy of aortopathies. As previously discussed, LV are optimal tools  
for the establishment of aortic models of disease and for a thorough analysis of mediators  
involved in their pathogeny, and constitute a reliable system for preclinical assessment of gene  
therapy suitability.  
  
Concluding remarks  
LVs have unique features that make them suitable for safe, long-term in vivo gene  
modification and can be easily engineered to improve biosafety and refine cell tropism. LVs are  
also emerging as valuable tools for dissecting molecular pathways involved in disease and can  
be applied to the design of efficient preclinical disease models. LV-based approaches have  
significant advantages over conventional gene ablation strategies. Unlike knockout models, LVs  
provide fast, time-controlled, and cell-, tissue- or even region-restricted gene expression  
modulation and allow simultaneous evaluation of the impact of gene manipulation in selected  
cell types. These characteristics show the singular properties of LVs not only for disease  
modeling, but also for evaluating the effectiveness of therapeutic gene modification and  
candidate molecules in preliminary stages of drug development (see Outstanding Questions).  
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ABBREVIATIONS  
AAV: Adeno associated virus  
AdV: Adenovirus  
Ang II: Angiotensin II  
ApoE: Apolipoprotein E  
EC: Endothelial cell  
GMP: Good Manufacturing Practices  
HIV: Human immuno deficiency virus  
HTLV1: Human T lymphotrophic virus or human T-cell leukemia-lymphoma virus.  
HSC: Hematopoietic stem cell.  
IDLV: Integration-deficient lentiviral vector  
IFN: Interferon  
LDL: Low density lipoprotein  
LEDGF: Lens epithelium-derived growth factor  
Lox: Lysyl oxidase  
LTR: Long terminal repeat  
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LV: Lentiviral vector  
MHC: Major histocompatibility complex  
MMP3: Matrix metalloprotease 3  
MT4-MMP: Membrane type-4 matrix metalloproteinase  
NOS2: Nitric Oxide Synthase 2  
SCID: Severe combined immunodeficiency  
ssRNA: Single-stranded RNA  
TGF: Transforming growth factor  
TIMP: Tissue inhibitor of metalloproteinase  
TLR: Toll like receptor  
LTR: Long terminal repeat  
VSMC: Vascular smooth muscle cell  
VSV-G: glycoprotein G of the vesicular stomatitis virus  






Adenovirus: Non-integrative, double-stranded DNA viruses without an envelope, which 
transduce dividing or non-dividing cells and can cause respiratory disease in humans. Modified 
versions of these viruses are used as vectors for gene delivery. 
Adeno-associated virus: Virus originally discovered as contaminants of adenovirus 
preparations. These single-stranded DNA viruses can infect both dividing and non-dividing cells 
and do not cause human disease. 
Aortic aneurysm: Pathological dilation of the aorta secondary to an alteration in aortic wall 
components. Aneurysms can appear at several locations (aortic root, thoracic aorta, 
abdominal aorta). Aneurysm rupture has a high mortality rate. 
Episome: Circular extra-chromosomal genetic material. 
Gammaretroviral vectors: Gamma retroviruses are RNA viruses that express reverse 
transcriptase and integrase. The reverse transcriptase converts the viral RNA into DNA, and the 
integrase integrates this DNA integrates into the host cell genome. Gamma retroviruses infect 
only dividing cells. 
Insertional mutagenesis: Generation of DNA mutations through the introduction of 
additional base pairs in the DNA sequence (in the case of LVs, mutations occur through the 
insertion of viral sequences into the host genome).  
Integration-deficient LVs (IDLV): LVs unable to insert their DNA into the host genome. IDLVs 
have an inactive integrase (the enzyme responsible for integration of viral genetic material into 
the DNA of the transduced cell). IDLVs give rise to episomes, which are progressively lost with 
cell divisions, resulting in transient transgene expression.  
Leukemogenesis: Process leading to the development of leukemia. Leukemogenesis is 
thought to be a multistep process involving structural and functional changes in a series of genes 
that result in the expansion of malignant cells. 
Marfan syndrome (MFS): Genetic disorder that affects connective tissue, mainly due to 
mutations in the Fibrillin1 gene. The resulting connective tissue alterations lead to a 
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characteristic appearance of MFS patients, who are usually tall, thin, and have long limbs and 
flexible joints. Patients also frequently have scoliosis and an increased incidence of mitral-valve 
prolapse and aortic aneurysm, which is the major cause of death in these patients. 
Pleiotropic LV: LVs with unrestricted tropism, which can transduce a variety of cell types. 
Self-deleting LV: LVs that, after integration into the host-cell DNA, are flanked by LoxP sites 
recognized by the recombinase Cre. Cre activity leads to recombination and subsequent excision 
of the viral sequences from host DNA. 
Systemic administration: Administration routes used to obtain a general distribution in the 
body. The route can be enteral (through digestive system) or parenteral (e.g. through 
intravenous or intraperitoneal injection). 
Restriction factors: Cellular proteins that block key steps in the virus life cycle, such as viral 
replication.  
Targeting: Modification of viral vector characteristics to achieve preferential transduction 
or transgene expression in a selected cell type.  
Transcytosis: Transport of macromolecules and viral particles across a cell. Transcytosis is a 
frequent mechanism in ECs, in which the protein albumin is transported through a specialized 
transcytosis mechanism. 
Transduction: Transfer of exogenous DNA into a cell by a viral vector. 
Viral tropism: Selectivity of a virus for a given host tissue, partially dependent on the 




BOX 1. HYBRID STRATEGIES FOR IMPROVING LV BIOSAFETY  
Mutational inactivation of LV class I integrase—the enzyme required for stable integration  
of viral sequences into host-cell DNA—has allowed the generation of IDLVs. Unlike class I  
integrase mutants, mutants of class II integrase display additional defects in viral assembly and  
reverse transcription. IDLVs remain as episomes in host-cell nuclei, where they support efficient  
transgene transcription. IDLVs have been used to develop hybrid strategies aimed at reducing  
insertional mutagenesis by LVs.  
1. Hybrid ZFN-LV techniques. Zinc-finger nucleases excise specific genomic DNA  
sequences by introducing double-strand breaks in the desired target gene. ZFNs have been used  
for targeted gene editing through homologous recombination. Simultaneous transduction of  
IDLVs encoding a ZFN and the DNA of interest allows the insertion of a particular transgene into  
a safe (e.g. noncoding) region of host DNA, thus minimizing the risk of random integration [77].  
2. Hybrid transposon-LV approaches. The Sleeping Beauty (SB) transposon allows  
integration of a sequence of interest into the target-cell genome with no preference for  
transcriptionally active regions. This system involves the interaction between the SB transposon  
inverted repeats (with reduced promoter/enhancer activity) and SB transposase. The  
cotransduction of IDLVs encoding SB transposase and an expression cassette flanked by SB  
inverted repeats redirects transgene integration away from transcriptionally active regions,  
reducing the probability of insertional mutagenesis [78].  
  
CLINICIAN’S CORNER BOX  
 Modified lentiviruses are commonly used as vectors for in vivo gene manipulation in  
preclinical models because they integrate into the host cell DNA, thus providing  
stable gene modification. In addition, modified lentiviruses have a good biosafety  
profile and do not trigger an intense host immune reaction. These characteristics can  
be further improved by engineering particular viral components.   
 Tropism of lentiviral vectors (LV) can be modified to selectively direct transgene  
expression toward a particular cell type. However, some groups have reported that  
effective transduction of VSMCs upon i.v. LV injection require additional EC injury.  
Nevertheless, efficient VSMC transduction has been achieved with intrajugular  
injection of LVs in the presence of an intact endothelium.  
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 LV-based systems have allowed to develop preclinical models of aortic aneurysm in 
normal mice in a rapid, versatile, and affordable manner. This approach also 
provides information about molecular mechanisms of aortic disease and potential 
therapeutic targets. 
 LVs are being evaluated in clinical trials either alone or as vectors for therapeutic cell 
transduction. A recent example of therapeutic cell transduction is CAR-T cells, 
lymphocytes with an LV-modified chimeric antigen receptor. These have been 
successfully used to treat blood malignancies such as acute lymphoblastic leukemia 
in children and diffuse large B-cell lymphoma in adults. Studies discussed here 
provide further evidence for the potential of LV as therapeutic tools in aortic disease.  
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FIGURE LEGENDS 
Figure1. Lentiviral-driven specific transgene expression in aortic layers. Mice received 
intrajugular injections of lentiviral vectors encoding either control or Adamts1 shRNAs and GFP 
protein. shRNAs expression was directed by hU6 promoter, and GFP by ubiquitous CMV 
promoter. Vectors were pseudotyped with VSVg envelope and 108 infective viral particles in 
100l were inoculated per mice. The pictures show staining with anti-GFP and anti-Adamts1 
antibodies of aortic sections at several levels 1 day after inoculation, as indicated. Transgene 
expression can be observed in all layers along the aorta. Figures reproduced with permission 
from Springer Nature. 
Figure2. Modulation of aortic aneurysm development through lentivirus-mediated 
genetic manipulation. A. Mice received intrajugular (i.j.) injections with lentiviral vectors 
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encoding either control or Adamts1 shRNAs, and were treated as indicated with vehicle (control)  
or angiotensin II (Ang-II). Graphs show the increase in maximum diameter of the aortic ring (left)  
and ascending aorta (middle) in mice injected with lentivirus encoding Adamts1 shRNA. Right,  
Staining of the ascending aorta with Masson’s trichrome (Masson) (top), elastic van Gieson (EVG)  
(middle), and Alcian blue (bottom), revealing characteristic features of medial degeneration  
similar to those induced by Ang-II observed in Adamts1 shRNA-treated mice. Yellow arrowheads  
indicate elastin breaks. B. ApoE-/-mice were inoculated i.j. with lentiviral vectors encoding a GFP- 
fused form of the calcineurin blocking peptide LxVP or its mutant version LxVPmut. Mice were  
Ang-II treated to induce abdominal aortic aneurysm formation. Left, GFP expression in abdominal  
aortic layers. Right, Expression of LxVP, but not LxVPmut, significantly reduces the Ang-II-induced  
increase in abdominal aorta diameter. C. 1-day-old Mmp17-/- mice were inoculated i.j. with  
lentiviral vectors encoding WT or the E248A catalytically inactive version of Mmp17. Photographs  
correspond to transmission electron microscopy images of thoracic aortic sections, showing  
recovery of extracellular matrix structure in WT but not E248A mutant Mmp17-injected mice.  
Figures reproduced with permission from Springer Nature (A), Rockefeller University Press (B),  
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Table 1. Main characteristics of commonly used viral vectors   
  
OUTSTANDING QUESTIONS 
 What is the mechanism of VSMC targeting by LVs in vivo, in the 
presence of an intact EC layer? 
 Is it possible that LVs cross the EC barrier by transcytosis? 
 Can a specific administration route (eg, tail vein vs. intrajugular) 
modulate LV tropism and promote transduction of a particular cell type? 
 Can LVs be used to model diseases other than aortopathies? 
 Do LVs show the same tropism in patients as observed in 
preclinical models? 
 Could aortic disease be reverted by gene therapy with a 
restricted aortic LV-transduction pattern? 
 Are results obtained for LV delivery of therapeutic molecules in 
preclinical models applicable in a clinical setting? 
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